Silex Systems Limited · ASX:SLX
Silex Systems — Investor Presentation (February 2024)
21 slides from Silex Systems's investor presentation, Feb 22, 2024
Slide 1: Investor Presentation
Silex Systems Limited For personal use only Investor Presentation (ASX: SLX) (OTCQX: SILXY) Dr Michael Goldsworthy CEO/Managing Director 22 February 2024 www.silex.com.au 1
Slide 2: Forward Looking Statements and Risk Factors
Forward Looking Statements and Risk Factors About Silex Systems Limited (ASX: SLX) (OTCQX: SILXY) Silex Systems Limited ABN 69 003 372 067 (Silex or Company) is a technology commercialisation company whose primary asset is the SILEX laser enrichment technology, originally developed at the Company’s
Slide 3: Our Mission: commercialise the SILEX laser enrichment technology
Our Mission: to commercialise the unique SILEX laser enrichment technology for application to: For personal use only Uranium production and Silicon enrichment Medical isotope enrichment enrichment (silicon quantum computing) (new cancer therapies) (nuclear power) Our strategy is focused on extractin
Slide 4: Highlights of the Half Year Review and Recent Developments
Highlights of the Half Year Review and Recent Developments Global Laser Enrichment (GLE) / SILEX Uranium Enrichment Technology Project: • GLE is positioning to leverage, via the SILEX technology, the ‘Triple Opportunity’ that has emerged in the global nuclear fuel market • GLE’s owners (Silex and Ca
Slide 5: Primary Focus on GLE Commercialisation
Primary Focus on GLE Commercialisation Uranium production and enrichment For personal use only (nuclear power) • SILEX uranium technology licencee Global Laser Enrichment (GLE) is progressing towards commercialisation • US-based GLE under JV ownership since 2021: 51% by Silex and 49% by Cameco Corpo
Slide 6: Nuclear Fuel Supply and Current Issues
Nuclear Fuel Supply and Current Issues The Nuclear Fuel Supply Chain For personal use only SILEX/GLE Opportunities Issues facing the Global Nuclear Fuel Supply Chain: - Western supply chain recent history - curtailments and under-investment in resources and production capability - Supply chain risks
Slide 7: US and EU Nuclear Fuel Requirements Supplied by Russia
US and EU Nuclear Fuel Requirements Supplied by Russia Russian Share of Global EU Nuclear Fuel US Nuclear Fuel Production Capacity1 Supplied by Russia2 Supplied by Russia1,3 Uranium (U308) ~14% ~20% ~14% For personal use only Conversion ~27% ~25% ~18% Enrichment (SWU) ~45% ~31% ~24% 1. WNA and UxC,
Slide 8: US Uranium and Enrichment Vulnerability
US Uranium and Enrichment Vulnerability US currently imports the vast majority of its nuclear fuel: - 95% of its uranium requirements (including ~14% from Russia) - 100% of its conversion requirements (including ~18% from Russia) For personal use only - 70% of its enriched uranium requirements (incl
Slide 9: Emerging Nuclear Fuel Supply Opportunities for GLE
Emerging Nuclear Fuel Supply Opportunities for GLE Uncovered Uranium Base Case Demand © UxC Million SWU Uncovered SWU Base Case Demand © UxC Million pounds U308 275 90 250 80 For personal use only 225 70 200 60 175 150 Non-U.S. Utilities 50 125 Non-U.S. Utilities United States 40 100 United States 3
Slide 10: Recent Nuclear Fuel Market Price Trends
Recent Nuclear Fuel Market Price Trends For personal use only Source: UxC • Global nuclear fuel markets are pricing in the impact of a bifurcating market precipitated by looming Russian fuel sanctions/exclusions • According to UxC, the uranium spot price has increased by ~300% from ~US$24/lb (2019)
Slide 11: Acceleration of GLE's Activities for the SILEX technology
Acceleration of GLE’s Activities for the SILEX technology GLE has unique potential to address the ‘Triple Opportunity’ that has emerged in the global nuclear fuel supply chain: • GLE joint venture owners Silex and Cameco approved a plan and budget for GLE in CY2024 that continues to support the acce
Slide 12: GLE's Potential Timelines for Commercialisation of SILEX technology
GLE’s Potential Timelines for Commercialisation of SILEX technology1 Baseline - GLE Commercialisation Timeline: PLEF Commercial Technology Demonstration2 PLEF3 Feasibility and Licensing PLEF EPC4 Operations For personal use only c. 2025 c. 2027 c. 2030+ Accelerated - GLE Commercialisation Timeline5:
Slide 13: Status of Technology Pilot Demonstration Project
Status of Technology Pilot Demonstration Project1 Laser Systems: - Two full-scale pilot laser system modules (designed and built by Silex), installed and commissioned in GLE’s Test Loop facility in Wilmington - Currently being prepared for TRL-6 enrichment testing For personal use only SILEX Technol
Slide 14: GLE's PLEF Production Plant Opportunity
GLE’s PLEF Production Plant Opportunity The PLEF Triple Opportunity Paducah Laser Enrichment Facility (PLEF) – an opportunity to deploy the SILEX technology in the US: • PLEF UF6 Production: Production of up to 5 million pounds (equivalent) natural grade uranium (as UF6) annually for up to 30 years
Slide 15: GLE's PLEF Multi-purpose Production Plant Opportunity
GLE’s PLEF Multi-purpose Production Plant Opportunity For personal use only Source: GLE, Multi-purpose PLEF (conceptual) www.silex.com.au 15
Slide 16: GLE's PLEF Production Plant Opportunities
GLE’s PLEF Production Plant Opportunities For personal use only * * GLE PLEF Process streams – NUF6 and LEU Production * DUF6: Depleted UF6 www.silex.com.au 16
Slide 17: PLEF UF6 Production Opportunity
PLEF UF6 Production Opportunity (Natural UF6 production from tails) Akin to a ‘Tier 1’ Potential Accelerated Equivalent U3O8 Uranium Resource* Production For personal use only Commercial Based on low cost and Operation Date^ longevity of production Up to 5 million lbs p.a. for approximately 30 years
Slide 18: GLE Value Proposition for Silex
GLE Value Proposition for Silex* 1) GLE Equity – Minimum 25%: • Silex currently holds 51% – Cameco has a call Option to acquire an additional 26% at fair market value • Option window opened 1 February 2023 – closes 30 months after successful TRL-6 demonstration For personal use only • Either way, Si
Slide 19: Significant Additional Opportunities
Significant Additional Opportunities For personal use only Silicon enrichment Medical isotope enrichment (silicon quantum computing) (new targeted beta cancer therapies) • SILEX technology proven capable of producing highly enriched silicon • Medical isotope project aiming to develop a process to en
Slide 20: Summary
Summary GLE’s path to market is underpinned by the PLEF UF6 project for cost effective production of natural uranium (in the form of UF6) and significant value of conversion contained in GLE’s feed inventories Acceleration of the technology pilot demonstration project continuing in CY2024, which if
Slide 21: Thank you
For personal use only Thank you www.silex.com.au 21
Silex Systems — Investor Presentation (February 2024) on 6ix